Biofrontera AG (BFRA) concluded trading on 08/26/20 at a closing price of $10.87, with 1.18 million shares of worth about $12.78 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -2.60% during that period and on Wednesday the price saw a gain of about 7.09%. Currently the company’s common shares owned by public are about 22.42M shares, out of which, 11.26M shares are available for trading.

A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 3 analysts are covering the BFRA stock and their offered price forecasts bring an average price target of $12.71. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $15.00 and could fall to a lowest price of $11.00. Analysts also issued an outlook of 2.00 for the Biofrontera AG stock for next 12 months. The stock’s current price level is 29.87% above of average price target set by the analysts, while a rise to estimated low would result in gain of 1.18 for the stock. However, touching the estimated high of $15.00 would mean a gain of 27.53% for the stock.

Biofrontera AG (NASDAQ: BFRA) started trading at $10.01, below -$0.14 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $10.87, or with a gain of 7.09%. Stock saw a price change of -2.60% in past 5 days and over the past one month there was a price change of 66.13%. Year-to-date (YTD), BFRA shares are showing a performance of 5.56% which decreased to -19.92% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.26 but also hit the highest price of $54.94 during that period. While comparing its average daily trading volume of 264.28K shares, we see that about 1.18 million changed hands on the day. The stock is currently trading -19.05% below its 20-day simple moving average (SMA20), while that difference is up 17.29% for SMA50 and it goes to -6.49% lower than SMA200.

Biofrontera AG (NASDAQ: BFRA) currently have 22.42M outstanding shares and institutions hold larger chunk of about 0.09% of that. Holding of mutual funds in the company is about — while other institutional holders and individual stake holders have control over — and — of the stake respectively.

The stock has a current market capitalization of $243.76M. It has posted earnings per share of -$0.76 in the same period. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BFRA, volatility over the week remained 21.83% while standing at 73.22% over the month.

Analysts are in expectations that Biofrontera AG (BFRA) stock would likely to be making an EPS of -$0.16 in the current quarter, while forecast for next quarter ESPS is -$0.38 and it is -$1.21 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.16 which is -$0.16 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.58 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -202.80% while it is estimated to decrease by -11.00% in next year.

Analysts at 3 brokerage firms have issued recommendations for the Biofrontera AG (BFRA)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 3 Wall Street analysts, 2 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Lake Street on May 20, 2020 offering a Buy rating for the stock and assigned a target price of to it. Coverage by The Benchmark Company stated Biofrontera AG (BFRA) stock as a Buy in their note to investors on April 20, 2020, suggesting a price target of $8 for the stock. On November 20, 2019, The Benchmark Company Reiterated their recommendations, while on October 11, 2019, Lake Street Downgrade their ratings for the stock with a price target of $11. Stock get a Buy rating from The Benchmark Company on June 21, 2018.